Fast-Track Development of Medications to Treat Cannabis Use Disorders (UG3/UH3)
Post Date
May 26th 2015
Application Due Date
May 7th 2018
Funding Opportunity Number
PAR-15-267
CFDA Number(s)
93.279
Funding Instrument Type(s)
Cooperative Agreement
Funding Activity Categories
Number of Awards
3
Eligibility Categories
State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Funding
-
Estimated Total Funding:
$3000000
-
Award Range:
$None - $1000000
Grant Description
The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the discovery and development of medications to treat Cannabis Use Disorders (CUDs) using the UG3/UH3 mechanism. The objective is to advance medications toward the ultimate goal of obtaining FDA approval. Advances in understanding the cannabinoid systems and the effects of marijuana on the brain, coupled with the availability of both novel and marketed medications that may be efficacious to treat these disorders, offer unprecedented opportunities to develop safe and effective pharmacotherapies for CUDs.
Contact Information
-
Agency
Department of Health and Human Services
-
Office:
National Institutes of Health
-
Agency Contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV -
Agency Mailing Address:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- Agency Email Address:
- More Information:
Get A Free Grant Assistance Kit
To start your application for a free grant package go to: